Around 570 000 @entity1 develop @entity0 worldwide. In the U.K. it affects 33 000 @entity1 and causes 16 000 deaths each year. Treatment of early @entity0 is surgical, comprising breast conserving surgery (followed by radiotherapy) for @entity5 , or mastectomy for @entity5 . Survival of @entity1 with @entity0 depends on two different types of prognostic factors: @entity5 size reflecting how long the @entity5 has been present, and biological factors (i.e. grade) which represent @entity5 . In @entity1 with a @entity5 that has adverse features predicting early recurrence (i.e. lymph node positivity, large size, high grade) adjuvant systemic chemo- or hormonal therapy is given to reduce the risk of relapse. Chemotherapy is given to pre-menopausal @entity1 for @entity2931 receptor negative post-menopausal @entity0 , whereas hormone therapy is reserved for @entity2931 receptor positive @entity5 . Since 50% of @entity1 will never relapse, identification of which @entity1 are at high risk of recurrence is necessary so as to offer treatment with adjuvant therapy. The use of hormone therapy and chemotherapy has been aided by factors predicting the likelihood of response, e.g. @entity2931 receptor status. The value of newer prognostic and predictive markers is addressed.

Prognostic and predictive factors in XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['small unifocal tumours', 'larger or multifocal tumours', 'tumour aggressiveness', 'cancer', 'tumour'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity2931 :: ('CHEBI:50114', 'Chemical') :: ['oestrogen']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
